CGTLive®’s Weekly Rewind – May 24, 2024
Review top news and interview highlights from the week ending May 24, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Atara Submits BLA for Tab-Cel EBV+ PTLD T-Cell Therapy
Tab-Cel is approved under the name Ebvallo in Europe, Switzerland, and United Kingdom.
2. Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
The Associate Professor of Neurology at Keck School of Medicine of USC discussed her talk on preparing for gene therapy administration.
3. CRISPR-Editing EBT-101 Therapy Safe, Temporarily Suppresses HIV Infection
Excision is evaluating a higher dose in a second cohort as well as exploring alternative, potentially redosable, delivery methods.
4. Erika Fullwood Augustine, MD, MS, on Optimizing End Points for Rare Disease Clinical Trials
The associate chief science officer of the Kennedy Krieger Institute discussed an aspect of clinical trial design highly relevant to gene therapy development for rare diseases.
5. NKGen’s Autologous NK Therapy Proceeds to Phase 2 Trial for Alzheimer Disease
Most participants had improved or stable cognitive function in a proof-of-concept study.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
